A pill for obesity that works like the blockbuster injectables? That’s the promise of Eli Lilly’s investigational oral GLP-1 receptor agonist, orforglipron — and the latest Phase 3 results suggest it’s the real deal.
The ATTAIN-1 Trial at a Glance
- Size: 3,127 adults with obesity or overweight + a related health condition (no diabetes)
- Design: 72 weeks, randomized, double-blind, placebo-controlled
- Locations: US, Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain, Taiwan
- Goal: Show that daily orforglipron beats placebo for weight loss
The Numbers That Matter
At the highest dose (36 mg, once daily, no food or water restrictions):
- 12.4% average weight loss (27.3 lbs) vs 0.9% (2.2 lbs) with placebo
- 59.6% of participants lost at least 10% of body weight
- 39.6% lost at least 15% of body weight
- Significant improvements in cholesterol, triglycerides, blood pressure, and inflammation (hsCRP ↓ 47.7%)
Even lower doses delivered meaningful results:
- 6 mg: −7.5% (17.2 lbs)
- 12 mg: −8.4% (19.0 lbs)
Safety Profile
- Mostly mild-to-moderate GI side effects — nausea, constipation, diarrhea, vomiting, indigestion
- No liver safety signal detected
- Discontinuation rates due to side effects: 5–10% for orforglipron vs 2.6% for placebo
Why It’s a Big Deal
Injectable GLP-1 drugs like semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) have reshaped the weight loss market. But daily pill form changes the game:
- No needles
- No cold-chain logistics
- Flexible dosing anytime of day
- Potential for earlier intervention and long-term adherence
Eli Lilly’s Kenneth Custer, Ph.D. summed it up:
“We’re working to transform obesity care with a convenient oral therapy that supports early intervention and long-term management.”
What’s Next
- Regulatory submission planned by year-end 2025
- Global launch prep underway
- More Phase 3 data coming this year, including trials in type 2 diabetes, obstructive sleep apnea, and hypertension
Bottom line: If approved, orforglipron could be the first serious oral rival to the GLP-1 injectables — and might lower the barrier for millions who want the benefits without the needle.
